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Background
T cells have proven to be effective for the treatment of leu-
kaemias in form of donor lymphocyte infusions (DLI).
However, those DLI are of unknown specificity and often
associated with graft versus host disease. New effector tools
in form of T cell receptor (TCR)-transgenic T cells with
specificity for leukaemia-derived human leukocyte antigen
(HLA) ligands are highly promising tools for the treatment
of life-threatening, therapy refractory leukaemias.
Material and methods
In order to identify leukaemia-derived HLA ligands, we
performed the immunopeptidomic approach on seven
samples from patients with myeloproliferative neoplasias
(MPN). HLA ligands derived from genes with expression
restricted to the hematopoeitc system were identified by
database searches and literature research and validated by
quantitative PCR (qPCR) and immunohistochemistry
(IHC). For isolation of peptide-specific TCR, naive T cells
of healthy blood donors were primed with single HLA-mis-
matched dendritic cells, pulsed with synthetic counterparts
of selected HLA ligands. Peptide specific T cells were iso-
lated using HLA multimers and cloned by limiting dilution.
TCR were isolated out of peptide-specific T cell clones and
characterised for their in vitro and in vivo leukaemia reac-
tivity as well as their in vitro on- and off-target reactivity.
Results
Using the immunopeptidomic approach on seven MPN
samples, we were able to identify 4386 unique HLA
ligands. Nineteen of those ligands are derived from seven
genes with restricted expression to the hematopoietic sys-
tem and are presented on six different HLA molecules.
We exemplarily selected the antigen myeloperoxidase
(MPO) (five identified ligands) and confirmed restricted
expression to myeloid cells. A TCR (named TCR2.5D6)
with high specificity for the HLA-B*07:02 restricted ligand
MPO5 could be isolated. TCR2.5D6-transgenic T cells
show in vitro leukaemia reactivity including colony form-
ing leukaemic progenitor cells. Strikingly, anti-leukaemic
reactivity could be observed in a murine model of human
acute myeloid leukaemia with HLA-B*07:02-transgenic
NB4 cells, resulting in significantly prolonged survival and
reduced bone marrow infiltration by leukaemic cells.
However, strong immune pressure led to the development
of tumours that lost transgene expression in the TCR trea-
ted group. Extensive experiments regarding safety of the
TCR2.5D6 revealed lack of reactivity against MPO- cells
including healthy hematopoietic stem cells. Experiments
with alanine variants of the MPO5-peptide resulted in a
recognition pattern that is unique for the MPO-specific
peptide.
Conclusion
In conclusion, as shown for the MPO-specific TCR, combi-
nation of the immunopeptidomic identification of leukae-
mia-derived HLA ligands with the isolation of TCR in the
single HLA-mismatched setting is suitable to generate highly
specific, leukaemia-reactive TCR-transgenic T cells. Further
TCR are isolated and characterized at the moment to allow
therapeutic application for a broad patient population.
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